Fig. 2From: Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)Five approved HDACis. To date, five HDACis have been approved by the FDA for the treatment of various cancers. However, only three approved HDACis, including romidepsin, belinostat, and chidamide, are in clinical application for PTCLsBack to article page